How to Organize Technical Documentation for Overseas Registration of Rehabilitation Devices?

Key Summary

Learn how to compile technical files for overseas registration of rehabilitation devices, including classification, reusable documents, core modules, common pitfalls, and a practical preparation checklist.

Key Summary

Preparing technical documentation for overseas registration of rehabilitation devices is not simply compiling all test reports and instructions into a binder. It requires reorganizing evidence of safety and performance into a logical chain that can be reviewed by regulators, following the target country's regulatory framework. Companies must first confirm whether the device falls within the target country's medical device regulatory scope, then determine classification and registration pathway based on intended use, mechanism of action, and risk class. Next, assess whether existing documents under NMPA, CE, FDA, ISO 13485, MDSAP and other systems can be reused. Core modules include product description, risk management, performance verification, clinical evaluation or clinical evidence, labels and instructions, software validation (if applicable), and sterilization or biocompatibility data.

Common risks include misclassification leading to the wrong registration pathway, outdated risk management standards, clinical evidence not accepted locally, labels or measurement units not meeting local requirements, and unclear responsibility for the authorized representative or certificate control. Companies should perform a gap analysis before starting, determine which documents can be reused and which must be localized, and arrange supplementary testing, notarization, translation and certification. This article provides a complete method from determination to compilation and includes a preparation checklist to reduce repeated work and deficiency corrections in multi-country registration.

Applicable Scenarios and Core Questions

Rehabilitation devices cover a wide range: physical therapy equipment, sports rehabilitation equipment, cognitive rehabilitation devices, rehabilitation robots, wheelchairs and walking aids, low- or mid-frequency electrical stimulators, ultrasound therapy devices, laser therapy devices, and pneumatic compression therapy devices. How technical documentation is organized directly determines the registration cycle and the number of deficiency corrections.

This article is intended for companies planning to export rehabilitation devices to GHWP member countries, Southeast Asia, the Middle East, Latin America, or markets referencing CE or FDA systems. Whether you are registering for the first time or expanding overseas with an existing domestic registration, technical documentation must be reorganized according to the target country's regulations.

Many companies fall into two extremes: one treats overseas registration as merely translating product standards into English; the other thinks it must start from scratch and redo all verification. In fact, the correct approach is to conduct a gap analysis first, then decide which materials can be reused and which need to be supplemented.

The core question is not whether the files are thick enough, but whether the files answer the regulator's three basic questions: What is the product? Is the product safe? Does the product achieve the claimed performance? All technical documentation must be structured around these three lines.

Registration Determination Logic

Before compiling technical documentation, the registration determination logic must be clarified to avoid directional errors. The first step is to confirm whether the product falls under the target country's medical device regulatory scope.

For rehabilitation devices, some products may be medical devices, while others may be personal health devices, exercise equipment, or ordinary furniture. For example, an ordinary massage chair that claims only muscle relaxation and makes no therapeutic claims may not be regulated as a medical device in many countries; but if it claims to relieve muscle spasm or improve blood circulation, it may be classified as a medical device. Companies must make an initial judgment based on the target country's laws and the product's intended use.

The second step is to determine the risk class and classification. Different countries use different classification rules, usually based on risk from low to high as Class I, II, III or Class A to D. Common rehabilitation devices: passive devices such as wheelchairs, walking aids, and orthoses are usually lower class; active devices such as electrical stimulators, ultrasound therapy devices, and rehabilitation robots are usually Class II or higher. Classification determines the registration pathway, technical documentation depth, and whether clinical trials are required.

The third step is to evaluate the reusability of existing documents. Companies should list current documents, including NMPA registration files, CE technical files, FDA 510(k) files, ISO 13485 system documents, MDSAP certificates, product test reports, risk management reports, and clinical evaluation materials.

The fourth step is to confirm localization requirements according to the target country. This includes language translation, standard revisions, local recognition of test data, label measurement units, and agent or authorized representative obligations. Only after completing these four steps can actual compilation begin.

Documentation and Evidence

Technical documentation for overseas registration of rehabilitation devices generally includes the following modules: product description and intended use, labels and instructions for use, design and manufacturing information, risk management documentation, performance verification data, clinical evaluation data, software declaration and validation documentation (if applicable), sterilization or microbiological documentation (if applicable), biocompatibility documentation, and stability and packaging verification data.

The product description must clearly state device name, model, structural composition, working principle, mechanism of action, body-contact materials, patient environment (e.g., hospital, home, clinic), intended user (professional or patient), and contraindications.

Risk management documentation is the core. It should follow the latest version of ISO 14971. The company must provide risk analysis, risk evaluation, risk control measures, overall residual risk evaluation, and a risk management report. If the product already has CE or FDA documentation, the risk analysis portion can often be reused, but changes to standard versions and local regulatory differences must be considered.

Performance verification data should be based on product technical requirements and target country standards. For example, electrical stimulation devices may need to comply with the IEC 60601 series, ultrasound therapy equipment may need IEC 60601-2-5 or IEC 60601-2-62, and rehabilitation robots may need mechanical safety, software, and usability standards. Test reports must be issued by qualified laboratories; some countries require reports from national laboratories or laboratories recognized under ILAC MRA.

Clinical evaluation is a difficult point in rehabilitation device registration. Low-risk devices may be exempt from clinical trials, but medium- and high-risk devices may require clinical literature evaluation, clinical study data, or real-world data. Acceptance of clinical evidence varies by country. For example, some Middle Eastern countries accept a CE clinical evaluation summary plus a local expert report; some Southeast Asian countries accept data from the country of origin plus a local clinical assessment.

Labels and instructions for use must comply with local language requirements. For example, Middle Eastern countries require Arabic; some Southeast Asian countries require the local language or English; Latin American countries require Spanish or Portuguese. Measurement units, symbols, and warning statements must comply with local regulations.

If the device contains software, a software description document and software lifecycle records must be provided. Many rehabilitation devices include apps or electronic control modules, and regulators are increasingly focusing on cybersecurity and usability.

Companies should also prepare the authorized representative and quality management system documentation. Most countries require overseas manufacturers to appoint a local agent or authorized representative and may require an ISO 13485 certificate.

Common Mistakes

Classification judgment errors: Submitting a low-risk product as high-risk, or vice versa, leading to wrong registration pathway, delays, or wasted fees.
Directly translating CE files without local adaptation: Different countries have different standard versions, language requirements, and regulatory terminology; direct translation often fails review.
Risk management documentation not updated to the latest standard: Some countries require ISO 14971:2019; using an older version will lead to deficiency requests.
Insufficient or unacceptable clinical evidence: Not confirming the target country's requirements for clinical data in advance results in challenges to the clinical evaluation.
Labels and instructions not meeting local regulations: Missing local language, statutory warnings, or incorrect measurement units.
No local agent or authorized representative appointed in time: Making the application impossible to submit or process.
Overlooking software documentation completeness: Rehabilitation devices often contain software; missing evidence of the software development lifecycle will cause rejection.
Not notarizing or certifying documents: Some countries require documents to be authenticated by the local embassy or certified by a translation company; omissions result in refusal.

Enterprise Preparation Checklist

Basic product documentation: model list, product photos, structural diagrams, working principle, intended use, contraindications.
Classification and registration pathway analysis table: classification result, registration type, applicant, cost, and time for each target country.
Existing system documentation: ISO 13485 certificate, MDSAP certificate, NMPA registration certificate and production license.
Risk management documentation: risk plan, risk analysis, risk evaluation, risk control, risk management report; ensure the latest version.
Performance verification reports: test reports executed according to target standards; confirm laboratory qualification.
Clinical evaluation materials: clinical literature, clinical studies, or exemption analysis.
Draft labels and instructions: written according to target country language and regulations, confirmed by regulatory affairs.
Software documentation: software description, requirements specification, verification report, cybersecurity statement (if applicable).
Authorized representative agreement: agreement and power of attorney signed with a local agent or authorized representative in the target country.
Notarization and translation arrangements: confirm in advance whether notarization, Apostille, or consular legalization is required, and schedule translation services.

AIMEILI Perspective

The most common misjudgment is treating overseas registration technical documentation as an English translation of product materials. In fact, the core of technical documentation compilation is the reconstruction of the evidence chain. It must be reorganized according to the target country's regulatory logic, not simply converted into another language. We recommend that companies conduct a gap analysis before starting. Spend two to three weeks clarifying: What is the product's classification in the target country? What test reports are needed? Will the clinical evidence be accepted? Is a local clinical trial needed? This avoids discovering major gaps midway.

With respect to reuse and localization, ISO 13485 certificates, basic R&D documents, risk analysis frameworks, and most performance verification reports can be reused. However, risk management reports, clinical evaluation reports, labels, instructions, and software documentation must be adjusted to target country requirements. In particular, many companies overestimate the global applicability of CE clinical evaluations. Middle Eastern, Southeast Asian, and Latin American countries may have additional requirements.

Local agents and certificate control must be given attention. A local agent is not only for submission and communication; it also bears legal responsibility. If certificate control is unclear, a change of agent could lead to the registration certificate becoming invalid or difficult to transfer.

For multi-country registration, build a base dossier that uniformly manages common content, and then establish country-specific variation files. This minimizes the risk of deficiencies and reduces repeated compilation. We recommend that companies design a data matrix in advance, mapping each country's review concerns, and conduct an internal pre-review before formal submission.

Frequently Asked Questions

Can CE technical files be fully referenced for overseas registration of rehabilitation devices?

No, they cannot be fully referenced. CE technical files can serve as a basis for many modules, but target countries may require different standard versions, test specifications, language, and clinical evidence. For example, CE may accept EN standards, while some Southeast Asian countries accept IEC or national standards. A gap analysis and conversion are necessary.

What should be done if clinical evaluation data is insufficient?

If clinical evaluation data is insufficient, first determine whether the product is exempt from clinical requirements. If so, provide the exemption rationale. If not, resolve the issue through scientific literature review, equivalent device comparison, or supplementary clinical trial data. It is advisable to consult the target country's registration authority or local agent early about specific clinical evidence requirements.

Can an authorized representative be changed? How can certificate control be ensured?

An authorized representative can be changed, but the change must be processed with the regulatory authority, including a waiver statement from the previous representative and an acceptance letter from the new one. The contract should clearly include clauses for certificate ownership transfer to ensure the manufacturer holds control of the registration certificate. Otherwise, a change of representative could result in invalidation or transfer delays.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI